Leading Factors of Progression in Patients with Cardiac Amyloidosis

被引:0
作者
Rameeva, A. S. [1 ]
Rameev, V. V. [1 ]
Bobkova, I. N. [1 ]
Safarova, A. F. [1 ]
Kobalava, Zh D. [1 ]
Moiseev, S., V [1 ]
机构
[1] Sechenov Univ, I M Sechenov Moscow State Med Univ 1, Moscow, Russia
关键词
AL-amyloidosis; amyloid cardiopathy; tissue dopplerometry; Strain Rate; chronic kidney disease; renocardial syndrome; NTproBNP; LIGHT-CHAIN AMYLOIDOSIS; EUROPEAN ASSOCIATION; AMERICAN SOCIETY; STAGING SYSTEM; AL-AMYLOIDOSIS; ECHOCARDIOGRAPHY; RECOMMENDATIONS; BIOMARKERS; UPDATE;
D O I
10.20996/1819-6446-2022-04-02.
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim. To describe prognostic meaning of cardiac and other principal clinical manifestations of systemic AL-amyloidosis in their interrelations. Material and methods. It has been made long-time survival analysis of 147 patients with systemic AL-amyloidosis. In the special investigation group (n=58) of AL (n=55) and ATTR (n=3) amyloidotic cardiopathy patients there were evaluated prognostically important structural and functional changes in myocardium with standard and impulse-wave tissue dopplerometric echocardiography in comparison with NTproBNP serum levels. Results. Even though significantly increased nowadays surviving of AL-amylodotic patients (Me=90 months) it has been found that as at previously time orthostatic hypotension and amyloid cardiopathy are being most severe initial syndromes (median 25 months), but after 1 year from diagnosis influence of these syndromes on surviving had decreased and most low surviving was more common in patients with CKD 3-5 (median 28 months). Influence of CKD 3-5 on surviving was associated predominantly with intracardial hemodynamics deterioration. Together with decreased systolic shortening strain rate (48,5%) decreased filtration rate (47,9%) was second of main factors contributing into NTproBNP increasing in effective multiple regression model (R=0,702, F(4,21)=5,095, p=0,005). NTproBNP level in less degree depended on renal clearance. Conclusion. Heart damage is one of the most prognostically unfavorable manifestations of systemic amyloidosis due to a sharp deterioration in the elastic properties of the myocardium, in the process of further development of amyloidosis, the leading factor in progression is the deterioration of the profile of cardiorenal interactions, the marker of which is the level of NTproBNP.
引用
收藏
页码:143 / 152
页数:10
相关论文
共 18 条
[1]   Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis [J].
Dispenzieri, A ;
Gertz, MA ;
Kyle, RA ;
Lacy, MQ ;
Burritt, MF ;
Therneau, TM ;
Greipp, PR ;
Witzig, TE ;
Lust, JA ;
Rajkumar, SV ;
Fonseca, R ;
Zeldenrust, SR ;
McGregor, CGA ;
Jaffe, AS .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) :3751-3757
[2]   Prognosis and Staging of AL Amyloidosis [J].
Dittrich, Tobias ;
Kimmich, Christoph ;
Hegenbart, Ute ;
Schoenland, Stefan O. .
ACTA HAEMATOLOGICA, 2020, 143 (04) :388-399
[3]   Amyloid diseases of the heart: assessment, diagnosis, and referral [J].
Dubrey, S. W. ;
Hawkins, P. N. ;
Falk, R. H. .
HEART, 2011, 97 (01) :75-84
[4]   Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis [J].
Gertz, MA ;
Comenzo, R ;
Falk, RH ;
Fermand, JP ;
Hazenberg, BP ;
Hawkins, PN ;
Merlini, G ;
Moreau, P ;
Ronco, P ;
Sanchorawala, V ;
Sezer, O ;
Solomon, A ;
Grateau, G .
AMERICAN JOURNAL OF HEMATOLOGY, 2005, 79 (04) :319-328
[5]   AL-amyloidosis with cardiac involvement. Diagnostic capabilities of non-invasive methods [J].
Gudkova, Alexandra Ya ;
Lapekin, Sergei, V ;
Bezhanishvili, Tinatin G. ;
Trukshina, Maria A. ;
Davydova, Victoria G. ;
Krutikov, Aleksandr N. ;
Kulikov, Aleksandr N. ;
Streltsova, Anna A. ;
Andreeva, Sofiia E. ;
Grozov, Roman, V ;
Poliakova, Anzhelika A. ;
Kostareva, Anna A. ;
Salogub, Galina N. ;
Shlyakhto, Evgenii, V .
TERAPEVTICHESKII ARKHIV, 2021, 93 (04) :487-496
[6]   Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements [J].
Kumar, Shaji ;
Dispenzieri, Angela ;
Lacy, Martha Q. ;
Hayman, Suzanne R. ;
Buadi, Francis K. ;
Colby, Colin ;
Laumann, Kristina ;
Zeldenrust, Steve R. ;
Leung, Nelson ;
Dingli, David ;
Greipp, Philip R. ;
Lust, John A. ;
Russell, Stephen J. ;
Kyle, Robert A. ;
Rajkumar, S. Vincent ;
Gertz, Morie A. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) :989-995
[7]  
KYLE RA, 1995, SEMIN HEMATOL, V32, P45
[8]   Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging [J].
Lang, Roberto M. ;
Badano, Luigi P. ;
Mor-Avi, Victor ;
Afilalo, Jonathan ;
Armstrong, Anderson ;
Ernande, Laura ;
Flachskampf, Frank A. ;
Foster, Elyse ;
Goldstein, Steven A. ;
Kuznetsova, Tatiana ;
Lancellotti, Patrizio ;
Muraru, Denisa ;
Picard, Michael H. ;
Rietzschel, Ernst R. ;
Rudski, Lawrence ;
Spencer, Kirk T. ;
Tsang, Wendy ;
Voigt, Jens-Uwe .
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2015, 16 (03) :233-271
[9]   Cardiac amyloidosis: in search of the ideal diagnostic tool [J].
Mavrogeni, Sophie I. ;
Vartela, Vasiliki ;
Ntalianis, Argyrios ;
Vretou, Rosa ;
Ikonomidis, Ignatios ;
Tselegkidou, Marini ;
Paraskevaidis, Ioannis ;
Markousis-Mavrogenis, George ;
Noutsias, Michel ;
Rigopoulos, Angelos ;
Kolovou, Genovefa ;
Kastritis, Efstathios .
HERZ, 2021, 46 (SUPPL 1) :9-14
[10]   Systemic amyloidosis from A (AA) to T (ATTR): a review [J].
Muchtar, E. ;
Dispenzieri, A. ;
Magen, H. ;
Grogan, M. ;
Mauermann, M. ;
McPhail, E. D. ;
Kurtin, P. J. ;
Leung, N. ;
Buadi, F. K. ;
Dingli, D. ;
Kumar, S. K. ;
Gertz, M. A. .
JOURNAL OF INTERNAL MEDICINE, 2021, 289 (03) :268-292